XML 102 R72.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 31, 2021 USD ($) Component Agreement PerformanceObligation Medicine | Jul. 31, 2015 USD ($) PerformanceObligation | Dec. 31, 2012 USD ($) | Dec. 31, 2021 USD ($) Component Agreement PerformanceObligation Medicine | Jun. 30, 2020 USD ($) | Dec. 31, 2021 USD ($) Component Agreement PerformanceObligation Medicine | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 810,456 | $ 729,264 | $ 1,122,599
R&D Revenue [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 468,061 | 364,565 | $ 770,149
AstraZeneca [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Deferred revenue | $ 0 |  |  | $ 0 |  | $ 0 | $ 10,000 |
AstraZeneca [Member] | Revenue [Member] | Strategic Partner [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Concentration percentage |  |  |  |  |  | 31.00% | 12.00% | 3.00%
AstraZeneca [Member] | R&D Revenue [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 254,600 | $ 88,000 | $ 28,100
Eplontersen Collaboration [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Upfront payment received | 200,000 |  |  |  |  |  |  |
Maximum amount of payments receivable for development and regulatory milestones | 485,000 |  |  | 485,000 |  | 485,000 |  |
Maximum amount of payments receivable for sales-related milestones | $ 2,900,000 |  |  | $ 2,900,000 |  | $ 2,900,000 |  |
Royalty percentage received on sales of medicine in U.S. |  |  |  |  |  | 20.00% |  |
Number of material components | Component | 4 |  |  | 4 |  | 4 |  |
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca |  |  |  |  |  | 55.00% |  |
Number of separate performance obligations | PerformanceObligation | 1 |  |  | 1 |  | 1 |  |
Transaction price | $ 200,000 |  |  | $ 200,000 |  | $ 200,000 |  |
Next prospective payment | 50,000 |  |  | 50,000 |  | 50,000 |  |
Revenue | 200,000 |  |  |  |  |  |  |
Research and Development Collaborations [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Cumulative payments received | $ 386,000 |  |  | $ 386,000 |  | $ 386,000 |  |
Number of collaboration agreements | Agreement | 2 |  |  | 2 |  | 2 |  |
Number of medicines currently being developed | Medicine | 6 |  |  | 6 |  | 6 |  |
Cardiovascular, Renal and Metabolic Diseases Collaboration [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Number of licensed medicines | Medicine | 5 |  |  | 5 |  | 5 |  |
Upfront payment received |  | $ 65,000 |  |  |  |  |  |
Number of collaboration agreements | Agreement | 1 |  |  | 1 |  | 1 |  |
Minimum amount of payments receivable for license fees and milestones | $ 5,500,000 |  |  | $ 5,500,000 |  | $ 5,500,000 |  |
Maximum amount of payments receivable for development milestones | 1,100,000 |  |  | 1,100,000 |  | 1,100,000 |  |
Maximum amount of payments receivable for regulatory milestones | 2,900,000 |  |  | 2,900,000 |  | 2,900,000 |  |
Maximum amount of payments receivable for commercialization milestones | 1,500,000 |  |  | 1,500,000 |  | 1,500,000 |  |
Number of separate performance obligations | PerformanceObligation |  | 1 |  |  |  |  |  |
Transaction price |  | $ 65,000 |  |  |  |  |  |
Next prospective payment | 10,000 |  |  | 10,000 |  | 10,000 |  |
Revenue |  |  |  | 10,000 |  | 10,000 |  |
Cardiovascular, Renal and Metabolic Diseases Collaboration [Member] | Minimum [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Cumulative payments received | 282,000 |  |  | 282,000 |  | 282,000 |  |
Cardiovascular, Renal and Metabolic Diseases Collaboration [Member] | Target for Metabolic Disease [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 30,000 |  |
Cardiovascular, Renal and Metabolic Diseases Collaboration [Member] | R&D Revenue [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Cumulative payments included in transaction price for performance obligation | $ 90,000 |  |  | $ 90,000 |  | $ 90,000 |  |
Oncology Collaboration [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Upfront payment received |  |  | $ 31,000 |  |  |  |  |
Number of collaboration agreements | Agreement | 1 |  |  | 1 |  | 1 |  |
Maximum amount of payments receivable for license fees and milestones | $ 160,000 |  |  | $ 160,000 |  | $ 160,000 |  |
Maximum amount of payments receivable for development milestones | 42,000 |  |  | 42,000 |  | 42,000 |  |
Maximum amount of payments receivable for regulatory milestones | 105,000 |  |  | 105,000 |  | 105,000 |  |
Next prospective payment | 12,000 |  |  | 12,000 |  | 12,000 |  |
Oncology Collaboration [Member] | Minimum [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Cumulative payments received | $ 141,000 |  |  | $ 141,000 |  | $ 141,000 |  |
Oncology Collaboration [Member] | ION736 [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Revenue |  |  |  |  | $ 13,000 |  | $ 13,000 |

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative payments received since inception of the collaboration agreement included in the transaction price for the performance obligation. + References No definition available. + Details
Name: | ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period. + References No definition available. + Details
Name: | ions_CumulativePaymentsReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for commercialization milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for development and regulatory milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForDevelopmentAndRegulatoryMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for development milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount of payments receivable for license fees and milestone payments under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for regulatory milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for sales-related milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForSalesRelatedMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The minimum amount of payments receivable for license fees and milestone payments under the collaboration agreement. + References No definition available. + Details
Name: | ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndMilestonePayments
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The next potential payment to be earned under the collaboration agreement. + References No definition available. + Details
Name: | ions_NextPotentialPayment
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of collaboration agreements with the collaboration partner. + References No definition available. + Details
Name: | ions_NumberOfCollaborationAgreements
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of medicines that have been licensed under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfLicensedMedicines
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of material components identified in the collaboration agreement under Accounting Standards Codification (ASC) 808, Collaborative Arrangements. + References No definition available. + Details
Name: | ions_NumberOfMaterialComponents
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of medicines currently being developed under the collaboration agreement(s). + References No definition available. + Details
Name: | ions_NumberOfMedicinesBeingDeveloped
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of costs associated with the ongoing global Phase 3 development program paid by a collaboration partner under the collaboration agreement. + References No definition available. + Details
Name: | ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner
Namespace Prefix: | ions_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of separate performance obligations under the collaboration agreement. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty percentage received on sales of a medicine in the United States by a collaboration partner under the collaboration agreement. + References No definition available. + Details
Name: | ions_RoyaltyPercentageReceivedOnSalesOfMedicineInUnitedStates
Namespace Prefix: | ions_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationEplontersenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_TargetForMetabolicDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_Ion736Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |